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remains debatable. As many as 300 (or 33.4%) out 
of 897 haemodialysis (HD) patients of our center 
were positive for HBV-antibodies. 'Isolated' anti- 
HBc (HBsAg, HBsAb were not found) were detected 
in 194 patients (64.7%), while HBsAb was found only 
in 31 patients (10.3%), and HBsAb together with 
HBcAb were found in 75 patients (25%). 
Methods: Twenty seven HD patients (age 44.3±2.6; 
15 males, 12 females)with 'isolated' HBcAb were 
randomly assigned for study a new approaches of 
immunization against HBV infection. Schedule of 
vaccination of A.Mclntyre et al. (1992) was adapted 
for HD patients. All patients were immunized by 
40 mcg of HBV vaccine 'Combiotech' (Russia). Blood 
samples were obtained for quantitative determina- 
tion of HBsAb in 1 month after the first vaccination. 
If the HBsAb titers were higher than 50mlU/ml, 
the immunization was terminated. In this case 
'isolated' HBcAb could be considered as a sign of 
past HBV infection. In patients with lower level of 
HBsAb vaccination was continued using a 'standard' 
schedule for HD patients (1-2-6 months). 
Results: The HBsAb titers a month after the end of 
immunization are shown in Table 1. 
Tab[e 1. Resu[ts of vaccination of patients with 'iso[ated' HBcAb 
and with HBsAb <50mlU/m[ one month after the first vaccine 
injection. 
HBsAb HBsAb (mlU/m[) at end of vaccination 
(mlU/m[) 1 mo after first injection 
< 10 10-99 100-499 < 500 Tota[ 
<10 1 3 2 - 6 
10-50 - 3 3 2 8 
Total 1 6 5 2 14 
Conclusion: Nearly half of the patients with the 
'isolated' HBcAb responded by a protective titer 
only after complete course of immunization. Pos- 
sibly the detection of this marker had pseudo- 
positive character. Thus, the suggested vaccination 
scheme allows one to increase its efficiency in HD 
patients with 'isolated' HBcAb. 
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Background E Methods: Vaccination efficacy 
against the HBV infection was studied in 175 
haemodialysis (HD) patients (96 males, 79 fe- 
males, 49±0.8 years old) who had no signs of 
HBV infection (no HBsAg, HBsAb and HBcAb). The 
duration of the HD therapy prior to immuniza- 
tion was 10.2±0.7 months. Chronic renal failure 
mainly resulted from chronic glomerulonephdtis in 
33.1% of patients, diabetic nephropathy (19.4%) 
and chronic pyelonephdtis (16.6%). Patients were 
immunized with "Engerix B" (GlaxoSmithKline) or 
"Combiotech" (Russia) by injecting 40 mcg of vac- 
cine at 0th, 1st, 2nd and 6th month. 
Results: The results were monitored for 36 months 
after the end of vaccination. In one month the 
HBsAb titers of 10 mlU/ml or higher were found in 
147 patients (84%). The dynamics of the level of the 
HBsAb titers during the next 36 months is shown in 
Table 1. The number of patients with the HBsAb 
titres less than 10mlU/ml divided by the number 
of patients having certain HBsAb level at the end 
of immunization is presented. 
Tabte 1. Number of patients with HBsAb < 10 mlU/m[ at different 
stages of fottow-up at different revers of post-immunization 
titres 
HBsAb 18mo 24mo 30mo 36mo 
(mlUlm[) (n =97) (n =78) (n = =69) (n =40) 
n % n % n % n % 
10-99 10/18 56 13/15 87 13/15 87 13/13 100 
100-499 4/25 16 5/16 31 6/13 46 8/9 89 
500 0/54 0 1/47 2 3/41 7 7/18 39 
Conclusion: The rate of decreasing of protective 
antibody titers in HD patients depended on re- 
sponse intensity at the end of vaccination. It may 
be the rationale for revaccination in HD patients. 
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Background: EBV related PTLD has been recog- 
nized as a serious complication of immunosuppres- 
sion in patients undergoing bone marrow trans- 
plants, and solid organ transplants. The presence of 
EBV related PTLD outside of the transplant world, 
has been reported less frequently. We report a 
case of biopsy confirmed polyclonal EBV PTLD in a 
patient with Crohns disease, and successful treat- 
ment with gancidovir. 
Case: A 17 yr female with a known history of 
Crohns disease presented in August with symptoms 
